Cipla inks distribution pact with US-based BioQ Pharma

Cipla on January 6, 2016 signed a strategic distribution, supply and development agreement with BioQ Pharma Incorporated, the US-based specialty pharmaceutical company focused on the development and commercialisation of single-use, large volume ready-to-use infusible pharmaceuticals, for the registration and commercialisation of BioQ Pharma’s Ropivacaine infusion pharmaceutical in India.
 
“We are very pleased to partner with BioQ Pharma in introducing the Ropivacaine unit-dose infusion system to patients and caregivers in India. We believe that this innovative product represents a significant evolution in enhancing the delivery of infusions and managing post-surgical pain,” said Nikhil Chopra, head of Cipla’s India business.
 
BioQ Pharma’s unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care. In particular, the Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution.
   
Josh Kriesel, President and CEO of BioQ Pharma, commented, “We believe India is an excellent market to help expand our objective of establishing a new standard of care in the presentation and administration of infusible pharmaceuticals. Cipla’s proven, hospital-focused sales and marketing organisation will be essential in introducing BioQ Pharma’s proprietary unit-dose, large volume infusion pharmaceuticals to India’s healthcare market, which we believe will benefit from our product’s value-add proposition of increased safety, sterility and convenience.”